Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Consumer Cyclical Healthcare Advertising Agencies Biotechnology
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Algernon Pharmaceuticals Inc. > AGN on FB: Screening for COVID patients started in Miami !!!
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(1161)
•••
Comment by Pandoraon Jul 28, 2020 10:37pm
145 Views
Post# 31334814

RE:AGN on FB: Screening for COVID patients started in Miami !!!

RE:AGN on FB: Screening for COVID patients started in Miami !!!
mattusvi wrote: AGN update on Facebook Live just moments ago. Sounds like screening for COVID patients started today at their Miami Florida site. The first patient dosed shouldn't be far off.

www.facebook.com/watch/?v=3560737253937573


Amazing what he says in there re recruiting patients for the trial. The Florida area is likely the biggest hot spot in the U.S. today re new positive cases and hospitalizations yet it is tough recruiting.

The hospitals all have funding packages with big pharma and they are restricted from associating with some small player like Algernon regardless of what the circumstances, consequences or outcomes might be. i.e. no compassion for the survivability of patients where money is involved.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities